We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prevention of Recurrent Venous Thromboembolism (PREVENT)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00000614
First Posted: October 28, 1999
Last Update Posted: March 16, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
National Heart, Lung, and Blood Institute (NHLBI)
  Purpose
A multicenter randomized, double blind placebo controlled trial to determine the efficacy of long-term, low dose warfarin in the secondary prevention of venous thromboembolism.

Condition Intervention Phase
Cardiovascular Diseases Heart Diseases Peripheral Vascular Diseases Thromboembolism Vascular Diseases Venous Thromboembolism Drug: warfarin Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Double
Primary Purpose: Prevention

Resource links provided by NLM:


Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):

Study Start Date: September 1998
Study Completion Date: August 2004
  Show Detailed Description

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   30 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
Patients with venous thromboembolism, including patients with factor V Leiden. Patients had completed prescribed anticoagulation therapy within the last two years before the trial and were not currently on anticoagulation therapy.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000614


Sponsors and Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Investigators
OverallOfficial: Robert Glynn Brigham and Women's Hospital
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00000614     History of Changes
Other Study ID Numbers: 117
R01HL057951 ( U.S. NIH Grant/Contract )
First Submitted: October 27, 1999
First Posted: October 28, 1999
Last Update Posted: March 16, 2016
Last Verified: September 2005

Additional relevant MeSH terms:
Vascular Diseases
Peripheral Vascular Diseases
Cardiovascular Diseases
Heart Diseases
Thromboembolism
Venous Thromboembolism
Peripheral Arterial Disease
Embolism and Thrombosis
Atherosclerosis
Arteriosclerosis
Arterial Occlusive Diseases
Warfarin
Anticoagulants